Researchers in the U.K. have won funding for a new developmental drug that could help reduce the risk of life threatening blood clots. The anticoagulant drug, called ichorcumab, is in development by researchers at Cambridge and just received an $11 million grant from Index Ventures, along with GlaxoSmithKline and Johnson & Johnson.
According to Cambridge researcher Jim Huntingdon, they began work on the drug after discovering a patient who was unable to form blood clots but also suffered no increased bleeding after a head injury in 2008. "This antibody can deliver a high degree of anticoagulation without increased bleeding; we've never seen that before," said Huntingdon.
The investment gives neither Glaxo nor Johnson & Johnson any preferential rights over the drug, but will allow them to keep closer tabs on its development.
For comments and feedback contact: editorial@rttnews.com
Health News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.